Sulfate-Reducing Bacteria: The Organisms Behind Hydrogen Sulfide SIBO

Behind every case of hydrogen sulfide SIBO is a population of sulfate-reducing bacteria doing exactly what evolution designed them to do: consuming hydrogen and sulfate and producing hydrogen sulfide. These organisms are not invaders. They are normal members of the human gut microbiome, present at low levels in roughly half of all healthy adults. The problem arises when conditions in the small intestine shift to favor their growth, allowing their population to expand and their H2S output to reach concentrations that damage intestinal tissue and produce systemic symptoms. Understanding the biology of sulfate-reducing bacteria, what they eat, how they grow, and what makes their waste product toxic, is the foundation for effective treatment of hydrogen sulfide SIBO.

The major sulfate-reducing bacteria species

Several genera of bacteria are capable of sulfate reduction in the human gut, but three are most clinically relevant. Desulfovibrio is the dominant genus, found in approximately 50% of healthy adults and present at significantly higher levels in patients with hydrogen sulfide SIBO and inflammatory bowel disease. Desulfovibrio piger is the most commonly identified species in the human gut. Bilophila wadsworthensis is a sulfite-reducing bacterium (it uses sulfite rather than sulfate as its terminal electron acceptor) that thrives on taurine-conjugated bile acids and is associated with high-fat, high-animal-protein diets. Fusobacterium species are also capable of producing hydrogen sulfide through cysteine desulfhydrase activity, breaking down the sulfur amino acid cysteine directly into H2S.

How SRB metabolism works

Sulfate-reducing bacteria use a form of anaerobic respiration called dissimilatory sulfate reduction. In simple terms, while human cells use oxygen as the final electron acceptor in their energy production chain, SRB use sulfate (SO4). The process requires two inputs: an electron donor (hydrogen gas or organic compounds like lactate) and sulfate. The output is hydrogen sulfide (H2S) and water. This metabolism gives SRB a competitive advantage in anaerobic environments where hydrogen is abundant. They compete directly with methanogenic archaea for hydrogen. In environments rich in sulfate, SRB outcompete methanogens because sulfate reduction is thermodynamically more favorable than methanogenesis. This is why some patients shift from a methane-dominant pattern to a hydrogen sulfide-dominant pattern over time.

The hydrogen that SRB consume is produced by other bacteria in the gut, primarily fermentative species that break down carbohydrates. This creates a syntrophic (mutually beneficial) relationship: fermentative bacteria produce hydrogen as a waste product of carbohydrate metabolism, and SRB remove that hydrogen, which actually benefits the fermentative bacteria by preventing hydrogen buildup that would inhibit their metabolism. In a healthy gut, this cross-feeding occurs at low levels and is balanced. In SRB overgrowth, the cycle amplifies, driving increased carbohydrate fermentation and increased H2S production.

What fuels SRB overgrowth

The competition between SRB and methanogens

Sulfate-reducing bacteria and methanogenic archaea compete for the same resource: hydrogen gas. This competition determines whether a patient's SIBO presents as hydrogen sulfide-dominant or methane-dominant. When sulfate is abundant (from dietary sources), SRB win the competition because sulfate reduction yields more energy per mole of hydrogen than methanogenesis. When sulfate is limited, methanogens prevail. This competitive dynamic has clinical implications. Treating methane-dominant SIBO can sometimes unmask or shift a patient toward hydrogen sulfide dominance if SRB are present. Conversely, reducing dietary sulfur can theoretically shift the balance back toward methanogens. The gut is not a static system, and the gas profile can change as bacterial populations shift in response to diet, antibiotics, and other factors.

How hydrogen sulfide damages the gut

Hydrogen sulfide at the concentrations produced by SRB overgrowth causes direct damage to the intestinal lining through several mechanisms. First, H2S inhibits butyrate oxidation in colonocytes and enterocytes. Butyrate is the primary fuel source for these cells, and blocking its use effectively starves the intestinal lining. Second, H2S disrupts tight junctions between epithelial cells, increasing intestinal permeability and allowing bacterial products to enter the bloodstream. Third, H2S triggers an inflammatory response in the intestinal mucosa, with increased production of pro-inflammatory cytokines. Fourth, at high concentrations, H2S is directly genotoxic, causing DNA damage in epithelial cells. These effects collectively produce the mucosal inflammation, barrier dysfunction, and symptom burden seen in H2S SIBO.

Systemic effects and neurotoxicity

Hydrogen sulfide does not stay in the gut. It is absorbed across the intestinal mucosa and enters the systemic circulation. At physiological concentrations, H2S serves important signaling functions, including vasodilation, neuromodulation, and anti-inflammatory effects. But at the elevated levels produced by SRB overgrowth, its effects become toxic. The most well-characterized systemic effect is inhibition of cytochrome c oxidase (Complex IV) in the mitochondrial electron transport chain. This is the same mechanism by which cyanide kills cells. The inhibition is reversible at sub-lethal concentrations but can significantly impair energy production in tissues with high metabolic demand, including the brain. This mitochondrial mechanism provides a plausible explanation for the brain fog, fatigue, and cognitive difficulties reported by many H2S SIBO patients.

Bladder symptoms (urgency, frequency, irritation) reported by some H2S SIBO patients may result from H2S effects on bladder smooth muscle and sensory nerves. H2S has been shown to modulate smooth muscle tone and sensory nerve activity in the urinary tract in animal models. Joint pain and generalized inflammation may reflect the systemic inflammatory effects of chronically elevated H2S levels. While these extraintestinal connections are biologically plausible and clinically observed, controlled studies specifically linking H2S SIBO to these symptoms are still limited.

Targeting SRB in treatment

Effective treatment of SRB overgrowth requires understanding their specific vulnerabilities. Bismuth compounds (bismuth subsalicylate, bismuth subnitrate) have direct antimicrobial activity against Desulfovibrio and other SRB by binding sulfide and disrupting bacterial cell membranes. Rifaximin affects SRB as part of its broad-spectrum activity against gram-negative anaerobes. Reducing dietary sulfur intake limits the sulfate substrate that SRB depend on. Addressing hypochlorhydria restores the gastric acid barrier that normally prevents SRB from colonizing the small intestine. Supporting motility through prokinetic agents helps clear SRB from the small intestine via restored MMC function. The multi-targeted approach is important because SRB can adapt to single interventions more readily than to combined strategies.